Piracetam
Used in disorders of cognitive processes, such as dementia and learning difficulties, memory and attention (Fesenko 2009), in vertigo, in cortical myoclonus and in the prevention of sickle cell crisis.
Given the lack of scientific evidence of its efficacy (Al Hajeri 2016, Flicker 2001), it is considered to be a drug of little therapeutic use (SEFAF 2012, INSALUD 2001).
Since the last update we have not found published data on its excretion in breast milk.
Its pharmacokinetic characteristics (low molecular weight, high oral bioavailability...) make its transfer into breast milk probable.
Side effects are rare and not serious (UCB 2013, AEMPS 2011).
It has been used in children in various studies (Di Ianni 1985, El-Hazmi 1996, Fesenko 2009). One study revealed several adverse effects (increased aggression, irritability and anxiety, among others) in children with Down syndrome who took Piracetam (Lobauhg 2001).
Given its proven lack of effectiveness and that it can transfer into breast milk, it is probably a non-essential medication during breastfeeding.
Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable, especially during the neonatal period and in case of prematurity.
If it is necessary to use it during breastfeeding, use the lowest effective dose and for the shortest possible period.
Alternatives
We do not have alternatives for Piracetam.
Very Low Risk
Compatible. Not risky for breastfeeding or infant.
Low Risk
Moderately safe. Mild risk possible. Follow up recommended. Read the Comment.
High Risk
Poorly safe. Evaluate carefully. Use a safer alternative. Read the Comment.
Very High Risk
Not recommended. Cessation of breastfeeding or alternative.
Synonyms
- Pyrrolidone Acetamide
Writings
- πιρακετάμη (Greek)
- بيراسيتام (Arabic)
- Пирацетам (Cyrillic)
- 吡拉西坦 (Chinese)
- ピラセタム (Japanese)
- Piracétam (French)
- C6H10N2O2 (Molecular formula)
- N06BX03 (ATC Code/s)
Drug trade names
References
- Al Hajeri A, Fedorowicz Z. Piracetam for reducing the incidence of painful sickle cell disease crises. Cochrane Database Syst Rev. 2016Abstract
- Barkat K, Ahmad M, Minhas MU, Malik MZ, Sohail M. Development of a simple chromatographic method for the determination of piracetam in human plasma and its pharmacokinetic evaluation. Drug Res (Stuttg). 2014Abstract
- UCB. Piracetam. Drug Summary 2013 Full text (in our servers)
- Fesenko UA. Piracetam improves children's memory after general anaesthesia. Anestezjol Intens Ter. 2009Abstract
- Flicker L, Grimley Evans G. Piracetam for dementia or cognitive impairment. Cochrane Database Syst Rev. 2001Abstract
- Lobaugh NJ, Karaskov V, Rombough V, Rovet J, Bryson S, Greenbaum R, Haslam RH, Koren G. Piracetam therapy does not enhance cognitive functioning in children with down syndrome. Arch Pediatr Adolesc Med. 2001Abstract
- AEMPS. Piracetam. Ficha técnica. 2001 Full text (in our servers)
- el-Hazmi MA, Warsy AS, al-Fawaz I, Opawoye AO, Taleb HA, Howsawi Z, Mohamed AA, Aly AW, Refai S, Sugathan PS, Rab AS, Ahmed HB, Abulaban M, Abdulkader AM, Farid M. Piracetam is useful in the treatment of children with sickle cell disease. Acta Haematol. 1996Abstract
- Di Ianni M, Wilsher CR, Blank MS, Conners CK, Chase CH, Funkenstein HH, Helfgott E, Holmes JM, Lougee L, Maletta GJ, et al. The effects of piracetam in children with dyslexia. J Clin Psychopharmacol. 1985Abstract